<DOC>
	<DOC>NCT00446199</DOC>
	<brief_summary>The purpose of this study is to determine the lowest effective dose of the study drug for the relief of moderate to severe vasomotor symptoms in postmenopausal women for 12 weeks.</brief_summary>
	<brief_title>Low-dose Hormone Therapy for Relief of Vasomotor Symptoms</brief_title>
	<detailed_description>This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc. Bayer HealthCare Pharmaceuticals, Inc. is the sponsor of the trial.</detailed_description>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Drospirenone</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Postmenopausal women &gt;40 years of age experiencing a minimum of 7 to 8 moderate to severe hot flushes per day or 50 to 60 moderate to severe hot flushes per week The usual exclusion criteria for hormone therapy apply Intake of medications other than hormones affecting hot flushes</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Vasomotor symptom relief</keyword>
	<keyword>Postmenopausal women</keyword>
	<keyword>Severe to Moderate Vasomotor symptoms</keyword>
</DOC>